Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study

American Journal on Addictions

Volumn 23, Issue 3, 2014, Pages 308-312

  Schnell, Thomas ^a,b   Koethe, Dagmar ^a,c   Krasnianski, Anna ^a   Gairing, Stefanie ^a   Schnell, Knut ^a,c   Daumann, Jörg ^a   Gouzoulis Mayfrank, Euphrosyne ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b University of Applied Sciences and Medical University   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGITATION; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FEVER; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING SCALE; HUMAN; HYPERSALIVATION; MALE; MEDICATION COMPLIANCE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; STRUCTURED INTERVIEW; UKU SIDE EFFECT RATING SCALE; COMPLICATION; MARIJUANA ABUSE; PSYCHIATRIC DIAGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEDICATION ADHERENCE; PILOT PROJECTS; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898824816     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2014.12126.x     Document Type: Article

References (20)

1. Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental outcomes: A systematic review. Lancet. 2007; 370: 319-328.
2. Green AI., Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. J Clin Psychiatry. 2006; 66 (Suppl. 6): 21-26.
3. Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005; 193: 379-386.
4. Baker AL, Hides L, Lubman DI., Treatment of cannabis use among people with psychotic or depressive disorders: A systematic review. J Clin Psychiatry. 2010; 71: 247-254.
5. Wobrock T, Soyka M., Pharmacotherapy of schizophrenia with comorbid substance use disorder-Reviewing the evidence and clinical recommendations. Prog Neuropsychopharm Biol Psychiatry. 2008; 32: 1375-1385.
6. Lubman DI, King JA, Castle DJ., Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry. 2010; 22: 191-201.
7. Kelly TM, Daley DC, Douaihy AB., Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012; 37: 1-24.
8. Murthy P, Chand P., Treatment of dual diagnosis disorders. Curr Opin Psychiatry. 2012; 25: 194-200.
9. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. J Clin Psychopharmacol. 2000; 20: 94-98.
10. Machielsen M, Beduin AS, Dekker N, et al. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol. 2012; 26: 189-195.
11. Brunette MF, Dawson R, O'Keefe CD, et al. A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn. 2011; 7: 50-63.
12. Schwieler L, Linderholm KR, Nilsson-Todd LK, et al. Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci. 2008; 83: 170-175.
13. Heresco-Levy U., Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 1113-1123.
14. Stahl SM, Shayegan DK., The psychopharmacology of ziprasidone: Receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003; 64 (Suppl 19): 6-12.
15. APA-American Psychiatric Association. 2000: Diagnostic and Statistical Manual of Mental Disorders-DSMIV-TR, Text Revision. 4th edn. American Psychiatric Association 2000; Washington, DC.
16. Kay SR, Kalathara M, Meinzer AE., Diagnostic and behavioral characteristics of psychiatric patients who abuse substances. Hosp Community Psychiatry. 1989; 40: 1062-1064.
17. Montgomery A, Asberg M., A new depression rating scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382-389.
18. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Act Psych Scand Suppl. 1987; 334: 1-100.
19. Hogan TP, Awad AG, Eastwood RA., Self-report scale, predictive of drug compliance in schizophrenics-Reliability and discriminant validity. Psychol Med. 1983; 13: 177-183.
20. Miller WR, Tonigan JS., Assessing trinker's motivation for change: The stages of readiness and treatment eagerness scale (SOCRATES). Psych Addict Behav. 1996; 10: 81-89.